Latest News

Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets
Read More
Designed by AI: the future of antibody drugs
Read More
Galux and HanAll Biopharma Initiate Strategic Collaboration to Develop AI-Designed Antibody Therapeutics for Cancer
Read More
Pioneering Precision: How South Korea's Galux is Redefining Antibody Discovery with AI
Read More
Korean AI firm Galux develops six novel therapeutic antibodies using innovative design methods
Read More
[Interview] DeepMind predicted proteins. A Korean startup says it's designing the future of antibodies.
Read More
Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets
Read More
Y-Biologics and Galux to co-develop AI-driven immune anticancer treatment
Read More
Galux Unveils Breakthrough AI Technology for Therapeutic Antibody Loop Design
Read More
Galux and LG Chem Initiate Joint Research on AI-Powered Cancer Drug Development
Read More
Galux to conduct joint research with LG Chem on cancer drug development
Read More
Showing 13-23 of 23 posts